Author: Zhang, Xiao-Nan; Liu, Jiang-Xia; Hu, Yun-Wen; Chen, Hui; Yuan, Zheng-Hong
Title: Hyper-activated IRF-1 and STAT1 contribute to enhanced Interferon stimulated gene (ISG) expression by Interferon α and γ co-treatment in human hepatoma cells Cord-id: 8txogxek Document date: 2006_9_30
ID: 8txogxek
Snippet: Abstract Previous reports suggest that type I and type II Interferon can co-operatively inhibit some virus replication, e.g. HCV, SARS-CoV, HSV-1. To find out the molecular mechanism underlying this phenomenon, we analyzed the transcription profile stimulated by IFN-α and IFN-γ in Huh-7 cells and found that the transcription of a subset of IFN stimulated genes (ISGs) including BclG, XAF1, TRAIL and TAP1 was enhanced when IFN-α and γ were both present. Promoter analysis of BclG revealed that
Document: Abstract Previous reports suggest that type I and type II Interferon can co-operatively inhibit some virus replication, e.g. HCV, SARS-CoV, HSV-1. To find out the molecular mechanism underlying this phenomenon, we analyzed the transcription profile stimulated by IFN-α and IFN-γ in Huh-7 cells and found that the transcription of a subset of IFN stimulated genes (ISGs) including BclG, XAF1, TRAIL and TAP1 was enhanced when IFN-α and γ were both present. Promoter analysis of BclG revealed that IRF-1 and STAT1 were both required in this process. Enhanced IRF-1/DNA complex formation was observed in interferon co-treatment group by gel shift analysis. Furthermore, IRF-1 activation was found to be generally required in this cluster of ISGs. STAT1 tyrosine phosphorylation was elevated by IFN combination treatment, however, only the hyper-transactivation of GAS but not ISRE was observed. In conclusion, hyper-activation of IRF-1 and elevated STAT1 dimer formation may be two general switches which contribute to a much more robust antiviral symphony against virus replication when type I and type II IFNs are co-administered.
Search related documents:
Co phrase search for related documents- activation capacity and acute respiratory syndrome cov: 1, 2
- activator signal transducer and acute respiratory syndrome cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- activator signal transducer and adaptive immunity: 1, 2
- activator signal transducer and luciferase activity: 1, 2, 3, 4
- activator signal transducer and lymphoma cell: 1
- active motif and acute respiratory syndrome cov: 1
- acute respiratory syndrome cov and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory syndrome cov and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome cov and lymphoma cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- adaptive immunity and lymphoma cell: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date